Introduction
The WT1 gene was originally isolated as a tumorsuppressor gene responsible for Wilms' tumor, a neplasm of the childhood (Call et al., 1990) . The WT1 gene encodes a protein with four zinc-fingers and is considered to be involved in transcriptional regulation of the genes such as PDGF-A chain (Gashler et al., 1992) , CSF-1 (Harrington et al., 1993) , IGF-II (Drummond et al., 1992) , IGF-IR (Werner et al., 1993) , and RAR-a (Goodyer et al., 1995) and in RNA metabolism (Larsson et al., 1995; Davies et al., 1998; Niksic et al., 2004) . Although the WT1 gene has been considered as a tumor-suppressor gene, the wild-type WT1 gene is overexpressed in primary human leukemia (Inoue et al., 1994) and a wide variety of solid cancers, including lung (Oji et al., 2002) , colon (Oji et al., 2003c) , esophageal (Oji et al., 2004c) , breast (Loeb et al., 2001; Miyoshi et al., 2002) , thyroid (Oji et al., 2003b) , pancreatic ductal cancer (Oji et al., 2004a) , head and neck squamous cell carcinoma (HNSCC) (Oji et al., 2003a) , astrocytic tumors (Oji et al., 2004b) , and bone and soft-tissue sarcoma (Ueda et al., 2003) . Moreover, the following findings indicated that the wild-type WT1 gene played oncogenic roles rather than tumor-suppressor functions in tumorigenesis of various types of cancers (Sugiyama, 2001) : (a) high expression levels of WT1 mRNA correlated with poor prognosis in leukemia (Inoue et al., 1994) and breast cancer and with high tumor stage in testicular germ-cell tumors (Harada et al., 1999) and HNSCC (Oji et al., 2003a) , (b) growth of WT1-expressing leukemia and solid cancer cells was inhibited by the treatment with WT1 antisense oligomers (Algar et al., 1996; Yamagami et al., 1996; Oji et al., 1999 Oji et al., , 2004a , (c) block of differentiation but induction of proliferation by constitutive expression of 17AA( þ )KTS( þ )WT1 isoform in response to granulocyte colony-stimulating factor (G-CSF) in 32D cl3 myeloid progenitor (Inoue et al., 1998 ) and normal myeloid cells , (d) bone marrow cells with high expression level of WT1 tended to develop into leukemia in the 7,12-demethylbenz(a)anthracene (DMVA)-induced rat leukemia (Osaka et al., 1997) , and (e) Lck promoter-driven 17AA( þ )KTS(À)WT1 isoform-transgenic mice showed block of differentiation in T lymphoid progenitor cells (Li et al., 2003) .
The WT1 gene is alternatively spliced at two sites: 17AA site, which consists of exon 5 of the WT1 gene, and KTS site, which exists between zinc-fingers 3 and 4, and yields four isoforms: (17AA( þ ) KTS( þ ), 17AA( þ )KTS(À), 17AA(À)KTS( þ ), and 17AA(À)KTS(À)), each of which is considered to have different functions. All of the four isoforms were expressed in primary human solid cancers, including lung cancer (Oji et al., 2002) , HNSCC (Oji et al., 2003a) , and sarcoma (Ueda et al., 2003) and human primary leukemia (Siehl et al., 2000) . Among the four WT1 isoforms, WT1 17AA( þ )KTS( þ ) isoform was dominantly expressed in all of the cancers examined. The results showing that constitutive expression of WT1 17AA( þ )KTS( þ ) isoform rescued the growth inhibitory effect of WT1 antisense oligomers on cancer cells indicated the contribution of WT1 17AA( þ )KTS( þ ) isoform to the growth of cancer cells (Hubinger et al., 2001) . As for the functions of WT1 17AA( þ )KTS(À) isoform, the results showing that lck promoter-driven 17AA( þ )KTS(À)WT1-transgenic mice blocked differentiation of T lymphoid progenitor cells, indicated the involvement of WT1 17AA( þ ) KTS(À) isoform in the tumorigenesis of lymphoid malignancy (Li et al., 2003) . As for 17AA(À)KTS(À) isoform, the results showing that 17AA(À)KTS(À)WT1 isoform induced G1 arrest in osteosarcoma cell lines (Englert et al., 1997) and inhibited G1/S progression and accelerated differentiation in 32D cl3 murine myeloid progenitor in response to G-CSF (Loeb et al., 2003) suggested tumor-suppressor roles in some tumors. As for 17AA(À)KTS( þ )WT1 isoform, its functions remain unclear. These results indicate that each of the WT1 isoforms has different functions and play important roles in leukemogenesis and tumorigenesis.
Cancers are characterized by abnormal control of proliferation. The WT1 gene is involved in the promotion of cell cycle, as it was indicated by findings that suppression of WT1 expression induced G2/M or G1 block in human leukemia K562 cells and HER2/neuoverexpressing breast cancer cells, respectively (Yamagami et al., 1998; Tuna et al., 2005) . Moreover, 17AA( þ )KTS(À)WT1 isoform increased the expression levels of antiapoptotic gene Bcl-2 in G401 rhabdoid cells (Mayo et al., 1999) , indicating that the WT1 gene might be involved in suppression of apoptosis. However, there is neither a direct evidence of antiapoptotic function of the WT1 gene nor analysis of precise mechanism of the function.
In the present study, we demonstrate that siRNA specific for 17AA( þ )WT1 isoforms induces apoptosis through activation of the intrinsic apoptosis pathway in WT1-expressing leukemia cells and that this apoptosis was associated with activation of proapoptotic Bax. Furthermore, stable expression of 17AA( þ )WT1 isoforms (17AA( þ )KTS( þ ) and 17AA( þ )KTS(À)) inhibited apoptosis induced by apoptosis-inducing agents, etoposide and doxorubicin, through inhibition of mitochondrial damages in leukemia cells.
Results

17AA
( þ )WT1-specific siRNA induces apoptosis in WT1-expressing leukemia cells To examine the roles of 17AA( þ )WT1 or 17AA(À)WT1 isoforms in protection of leukemia cells from apoptosis, 17AA( þ )WT1-and 17AA(À)WT1-specific siRNA vectors were constructed. RT-PCR and Western blot analysis showed that transient expression of 17AA( þ )WT1-and 17AA(À)WT1-specific siRNA vectors specifically suppressed expression of 17AA( þ ) WT1 and 17AA(À)WT1 isoforms, respectively, in K562 cells ( Figure 1A ). Three WT1-expressing leukemia cell lines (K562, HL-60, and Kasumi1) and one WT1-nonexpressing lymphoma cell line (Daudi) were transfected with 17AA( þ )WT1-specific siRNA, 17AA(À)WT1-specific siRNA, or control mock vector and incubated for 16 h. Annexin V-propidium iodide (PI) two-color flow cytometry showed that transient expression of 17AA( þ )WT1-specific siRNA induced apoptosis in all the three WT1-expressing leukemia cell lines, but not in WT1-non-expressing lymphoma cell line ( Figure 1B ). On the other hand, transient expression of 17AA(À) WT1-specific siRNA did not induce apoptosis in any of the three WT1-expressing leukemia cell lines and in one WT1-non-expressing lymphoma cell line. Furthermore, the cells treated with the 17AA( þ )WT1-specific siRNA were analysed for mitochondrial cytochrome c release and loss of mitochondrial membrane potential (MMP) by Western blot and flow cytometry, respectively. Transient expression of 17AA( þ )WT1-specific siRNA induced mitochondrial cytochrome c release and loss of MMP in WT1-expressing K562 cells, but not in WT1-non-expressing Daudi cells ( Figure 1C and D) . Furthermore, 17AA( þ )WT1-specific siRNA vector-transfected cells were labeled by expression of GFP protein using Gene Silencer pGSU6 shRNA Vector Kit system. As shown in Figure 1E , apoptosis was induced only in the 17AA( þ )WT1-specific siRNA vector-transfected cells, but not in the cells that were not transfected with 17AA( þ )WT1-specific siRNA vector. These results indicated the antiapoptotic roles of 17AA( þ )WT1 isoforms in WT1-expressing leukemia cells.
Transfection of 17AA( þ )WT1-specific siRNA induce apoptosis through activation of intrinsic but not extrinsic apoptosis pathway 17AA( þ )WT1-specific siRNA vector was transiently expressed in K562 cells for 16 h in the presence or absence of caspase inhibitors. Annexin V-PI two-color flow cytometry showed that pan-caspase inhibitor zVAD-fmk inhibited the apoptosis, indicating that 17AA( þ )WT1-specific siRNA induced apoptosis in a caspase-dependent manner (Figure 2A ). Block of apoptogenic signals by a caspase-3 inhibitor Ac-DEVD-CHO, at a point where the intrinsic apoptosis pathway and the extrinsic one meet, and of apoptogenic signals by caspase-9 inhibitor Ac-LEHD-CHO, at a point downstream of the mitochondria in the intrinsic pathway, inhibited apoptosis induced by 17AA( þ )WT1-specific siRNA. On the other hand, block of apoptogenic signals by caspase-8 inhibitor Ac-IETD-CHO at a point in the extrinsic pathway did not inhibit the apoptosis.
To examine the activation of apoptosis pathway by 17AA( þ )WT1-siRNA, activities of caspase-3, -8, and -9 were examined by fluorometric assay at various time points after transfection of 17AA( þ )WT1-specific siRNA. Activities of caspase-3 and -9 were significantly increased in 17AA( þ )WT1-specific siRNA-transfected K562 cells compared to mock vector-transfected K562 cells. However, activity of caspase-8 was not increased compared to mock vector-transfected K562 cells ( Figure 2B ). Moreover, to examine whether the extrinsic pathway was involved in the mitochondrial damages induced by 17AA( þ )WT1-specific siRNA, mitochondrial cytochrome c release was analysed in the presence or absence of caspase inhibitors 16 h after the transfection of 17AA( þ )WT1-specific siRNA ( Figure 2C ). Western blot analysis showed that block of apoptogenic signals by caspase-8 inhibitor, Ac-IETD-CHO, at a branching point from the extrinsic apoptosis pathway to the intrinsic one did not inhibit mitochondrial cytochrome c release, confirming that the extrinsic apoptosis pathway was not involved in mitochondrial damages induced by 17AA( þ )WT1-specific siRNA.
These results indicated that 17AA( þ )WT1-specific siRNA induced apoptosis through activation of the intrinsic apoptosis pathway but not through activation of the extrinsic pathway in leukemia cells, and thus that the 17AA( þ )WT1 isoforms played antiapoptotic roles in the intrinsic apoptosis pathway, but not in the extrinsic one.
Transfection of 17AA( þ )WT1-specific siRNA activates Bax Since 17AA( þ )WT1 isoforms were shown to play antiapoptotic roles in the intrinsic apoptosis pathway, the effect of suppression of 17AA( þ )WT1 isoforms on activation of Bax, which is considered to act as a gateway for various apoptotic signals at the mitochondria, was analysed. The 17AA( þ )WT1-specific siRNA vector was transiently expressed in WT1-expressing K562 leukemia cells for 16 h, and oligomerization of Bax was examined by Western blot analysis. As shown in Figure 2D , transfection of 17AA( þ )WT1-specific siRNA induced dimerization and oligomerization of Bax in K562 leukemia cells. These results indicated that 17AA( þ )WT1 protein acted to inhibit apoptosis at some point upstream of mitochondria in the intrinsic apoptosis pathway.
Stable expression of 17AA( þ )WT1 isoforms protects leukemia cells from apoptosis induced by apoptosisinducing agents through stabilization of mitochondrial membrane potential To confirm that 17AA( þ )WT1 isoforms had antiapoptotic functions, K562 cell clones that stably expressed one each of four WT1 isoforms at high levels were isolated (Figure 3a) . These cell clones were treated with apoptosis-inducing agents, etoposide or doxorubicin, for 24 h and analysed for apoptosis. Annexin V-PI two-color flow cytometric analysis showed that stable expression of 17AA( þ )WT1 isoforms significantly inhibited etoposide-induced apoptosis in K562 cells (Figure 3b ). On the other hand, stable expression of 17AA(À)WT1 isoforms (17AA(À)/KTS( þ ) and 17AA(À)/KTS(À)WT1 isoforms) did not inhibit etoposide-induced apoptosis. Similarly, stable expression of 17AA( þ )WT1 isoforms significantly inhibited doxorubicin-induced apoptosis in K562 cells, but that of 17AA(À)WT1 isoforms did not (Figure 3c ). These results confirmed the antiapoptotic functions of 17AA( þ )WT1 isoforms in leukemia cells.
Since it was well known that apoptosis-inducing agents such as etoposide and doxorubicin initiated cell death primarily by triggering the mitochondrial (intrinsic) apoptosis pathway, we next examined whether or not stable expression of 17AA( þ )WT1 isoforms protected mitochondrial membrane damages induced by etoposide or doxorubicin. K562 cell clones transduced with one each of four WT1 isoforms were treated with etoposide or doxorubicin for 24 h and analysed for mitochondrial cytochrome c release and loss of MMP by Western blot and flow cytometry, respectively. Stable expression of 17AA( þ )WT1 isoforms significantly blocked etoposide-induced release of cytochrome c from mitochondrial membrane ( Figure 4a ) and inhibited loss of MMP in K562 cells (Figure 4b ). On the other hand, stable expression of 17AA(À)WT1 isoforms inhibited neither mitochondrial cytochrome c release nor the loss of MMP induced by etoposide. Similarly, stable expression of 17AA( þ )WT1 isoforms inhibited both doxorubicin-induced release of cytochrome c from mitochondrial membrane and loss of MMP, whereas stable expression of 17AA(À)WT1 isoforms did not (Figure 4c and d). These results indicated that stable expression of 17AA( þ )WT1 isoforms stabilized mitochondrial membrane and protected leukemia cells from apoptosis induced by apoptosis-inducing agents.
17AA( þ )WT1 isoforms require zinc-finger region for the antiapoptotic functions
To examine subcellular localization of four WT1 isoforms, vectors that expressed polyhistidine-tagged one each of four WT1 isoforms were constructed and stably expressed in K562 leukemia cells (Figure 5a and b). As shown in Figure 5c , it was confirmed that stable expression of polyhistidine-tagged 17AA( þ )WT1 isoforms significantly inhibited etoposide-induced apoptosis but that of polyhistidine-tagged 17AA(À)WT1 isoforms did not. Then, localization of polyhistidinetagged WT1 protein was analysed by immunocytochemistry using an anti His-tag antibody. Confocal microscopic analysis showed that all of the four polyhistidine-tagged WT1 isoforms were detected in the nucleus but not in the cytoplasm and mitochondria in K562 leukemia cells (Figure 5d ). These results raised the possibility that nuclear-localized 17AA( þ )WT1 isoform proteins transcriptionally regulated some molecule(s) that directly acted on mitochondrial membrane and that let the mitochondria stabilize.
Furthermore, to examine whether or not zinc-finger motif (exons 7-10) of the 17AA( þ )WT1 isoforms were required for its antiapoptotic functions, polyhistidinetagged 17AA( þ )WT1 protein lacking zinc-finger motif (WT1DZF) was stably expressed in K562 leukemia cells ( Expression of proapoptotic Bcl-2 family member Bak was decreased by constitutive expression of 17AA( þ )KTS(À)WT1 isoform To examine the mechanisms by which 17AA( þ )WT1 isoform exerts its antiapoptotic functions, the protein expression levels of a set of known apoptotic-related genes such as CDK inhibitors p21 and p27, proapoptotic Bcl-2 familiy members Bax and Bak, antiapoptotic Bcl-2 family members Bcl-2 and Bcl-XL, and caspase-9 were analysed by Western blot in K562 leukemia cells transduced with one each of four WT1 isoforms. As shown in Figure 6a and b, the expression levels of proapoptotic Bak protein were significantly decreased in 17AA( þ )KTS(À)WT1 isoformtransduced K562 cells compared to other three WT1 isoform-transduced ones. On the other hand, expression levels of Bax, Bcl-2, Bcl-XL, p21, p27, and caspase-9 were not different among the four WT1 isoform-transduced K562 cells. These results showed that constitutive expression of 17AA( þ )KTS(À)WT1 ) ) and incubated for 16 h in the presence or absence of broad caspase inhibitor (zVADfmk), capsase-3 inhibitor (Ac-DEVD-CHO), capsase-9 inhibitor (Ac-LEHD-CHO), and capsase-8 inhibitor (Ac-IETD-CHO). Then, cells were analysed for apoptosis by Annexin V-PI two-color flowcytometry. zVAD, pan caspase inhibitor zVAD-fmk; C-3, caspase-3-specific inhibitor Ac-DEVD-CHO; C-9, caspase-9-specific inhibitor Ac-LEHD-CHO; and C-8, caspase-8-specific inhibitor Ac-IETD-CHO. (B) Activation of caspases by 17AA( þ )WT1-specific siRNA. K562 cells (2 Â 10 6 cells) were transfected with 10 mg of 17AA( þ )WT1-specific siRNA vector (WRI17AA( þ )), or empty siRNA vector by electroporation, incubated, and collected at the indicated time points. Caspases 3-, 8-, and 9-like activities were measured by fluorometric assay using Ac-DEVD-AFC, FAM-LEHD-FMK, and IETD-pNA, respectively, as substrates. Open column, empty siRNA vector-treated and closed column, 17AA( þ )WT1-specific siRNA-treated. zVAD: As a negative control for assays, K562 cells were transfected with WRI17AA( þ )-specific siRNA and incubated with broad caspase inhibitor zVAD-fmk (100 mM) for 24 h. ETP: As a positive control for caspases 3-and 9-like activities, K562 cells were treated with etoposide (100 mM) for 24 h. TRAIL: As a positive control for caspase-8-like activity, K562 cells were treated with TRAIL (500 ng/ml) for 5 h. Experiments were independently performed three times. bars, s.e. (C) Mitochondrial release of cytochrome c by 17AA( þ )WT1-specific siRNA. K562 cells were transfected with 17AA( þ )WT1-specific siRNA vector (WRI17AA( þ )) and incubated for 16 h in the presence or absence of caspase inhibitors. Representative results of Western blot analysis for mithochondrial release of cytochrome c are shown. zVAD, pan caspase inhibitor zVAD-fmk; C-3, caspase-3-specific inhibitor Ac-DEVD-CHO; C-9, caspase-9-specific inhibitor Ac-LEHD-CHO; and C-8, caspase-8-specific inhibitor Ac-IETD-CHO. (D) Bax activation by the transfection of 17AA( þ )WT1-specific siRNA was examined by Western blot analysis. *, monomer; **, dimer; and ***, oligomer of Bax protein.
isoform decreased expression levels of proapoptotic Bcl-2 family member Bak.
Discussion
Accumulating findings indicate that the WT1 gene plays oncogenic roles in tumorigenesis of various kinds of cancers. As for the mechanisms by which the WT1 gene exerts its oncogenic functions, two possible mechanisms, promotion of cell-cycle progression and suppression of apoptosis, may be raised. We and others have reported that suppression of WT1 expression induced G2/M or G1 block in human leukemia K562 cells and HER2/neuoverexpressing breast cancer cells, respectively (Yamagami et al., 1998; Tuna et al., 2005) . These results indicated the involvement of the WT1 gene in cell-cycle progression in cancer cells. Suppression of apoptosis by the WT1 gene was indicated by the findings that targeted disruption of the WT1 gene resulted in enhanced apoptosis and embarrassed normal development of organs, including kidney (Kreidberg et al., 1993; Davies et al., 2004) , retina (Wagner et al., 2002) , and spleen (Herzer et al., 1999) in mice. However, whether or not the WT1 gene could suppress apoptosis in leukemia cells and what were precise mechanisms if it had an antiapoptotic function remained unknown. In the present study, we demonstrated a novel oncogenic function of the WT1 gene to stabilize MMP and to inhibit apoptosis in human leukemia cells and showed that the antiapoptotic function of the WT1 gene was exerted by 17AA( þ )WT1 isoforms (17AA( þ )KTS( þ ) and 17AA( þ )KTS(À)) among the four WT1 isoforms. Thus, the WT1 gene exerted an oncogenic function via both promotion of cell-cycle progression and suppression of apoptosis.
It is important to determine whether or not 17AA( þ )WT1 proteins acted at the mitochondria in leukemic cells to understand the mechanism by which 17AA( þ )WT1 isoforms block the apoptotic mitochondrial permeabilization. Polyhistidine-tagged 17AA( þ ) WT1 proteins localized in the nucleus and inhibited etoposide-induced apoptosis. These results raised the possibility that nuclear-localized 17AA( þ )WT1 isoform proteins transcriptionally regulated some molecule(s) that directly acted on mitochondrial membrane and let the mitochondria stabilize. This was supported by the findings that proapoptotic Bcl-2 family member Bax, which was activated at a point upstream of the mitochondria, was activated by suppression of expression of 17AA( þ )WT1 isoforms in leukemic cells. Therefore, protein expression levels of a set of known apoptosis-related genes such as CDK inhibitors, proapoptotic Bcl-2 family members, antiapoptotic Bcl-2 family members, and caspase-9 were examined in K562 cells transduced with one each of four WT1 isoforms. Expression of proapoptotic Bcl-2 family member Bak was significantly decreased in 17AA( þ ) KTS(À)WT1 isoform-transduced K562 cells compared to other three WT1 isoform-transduced and control vector-transduced ones (deleted). Since Bak was considered to act as a gateway for various apoptotic signals at the mitochondria, decreased expression of Bak might be one of the mechanisms by which 17AA( þ )KTS(À) WT1 isoform exerted its antiapoptotic functions in leukemia cells. As for antiapoptotic Bcl-2 family genes, it was reported that 17AA( þ )KTS(À)WT1 isoform functioned as a transcription factor in G401 rhabdoid cells and increased the expression levels of antiapoptotic gene Bcl-2 (Mayo et al., 1999) . However, both expression levels of Bcl-2 and Bcl-XL in 17AA( þ ) KTS(À)WT1 isoform-transduced K562 cells were not different from those in control vector-transduced ones. 
In the present study, it was shown that wild-type 17AA( þ )WT1 isoforms inhibited apoptosis induced by apoptosis-inducing agents, whereas a mutant 17AA( þ ) WT1 isoform lacking zinc-finger region (exons 7-10) did not. These results indicated that zinc-finger region was essential for the antiapoptotic functions of 17AA( þ ) WT1 isoforms. Since zinc-finger region was DNAbinding site of the WT1 gene, these results indicated that the antiapoptotic function of WT1 17AA( þ ) isoforms operated through transcriptional regulation of the other genes. As for downstream targets of 17AA( þ )WT1 isoforms, proapoptotic Bak might be a direct or indirect target of 17AA( þ )KTS(À)WT1 isoform as shown in the present study. As for the downstream target of 17AA( þ )KTS( þ )WT1 isoform, we could not determine it. However, since this isoform has an insertion of three amino acids (lysine, threonine, and serine (KTS)), by which binding of 17AA( þ ) KTS( þ )WT1 isoform to a consensus sequence as that for 17AA( þ )KTS(À)WT1 isoform was abrogated, 17AA( þ )KTS( þ )WT1 isoform may transcriptionally regulate other gene(s) than one(s) regulated by 17AA( þ )KTS(À)WT1 isoforms (Reynolds et al., 2003) . Comprehensive studies, including microarray analysis are being planned to identify the targets of 17AA( þ ) KTS( þ )WT1 isoform. Interestingly, both the KTS( þ ) and KTS(À)WT1 isoforms required 17AA( þ ) region for their antiapoptotic functions, suggesting the necessity of the interaction with some molecule(s) through this region for their antiapoptotic functions. Taken together, these results may indicate that 17AA( þ ) KTS( þ ) and 17AA( þ )KTS(À)WT1 isoforms recruit some molecule(s) through the 17AA region, bind to their different target sequences through their zinc-finger regions, and regulate the transcription of target genes to play antiapoptotic roles.
Our data showed that 17AA( þ )WT1 isoforms exert antiapoptotic functions in leukemia cells through stabilization of mitochondrial membrane potential. Most chemotherapeutic drugs are considered to initiate cell death primarily by triggering the mitochondrial apoptosis pathway (Shimizu et al., 1996) . Constitutive expression of 17AA( þ )WT1 isoforms resulted in resistance of K562 leukemic cells to the apoptosisinducing chemotherapeutic reagent such as etoposide and doxorubicin. Thus, antiapoptotic function of 17AA( þ )WT1 isoforms through stabilization of MMP may contribute to chemotherapy resistance in leukemia. Recently, we analysed the expression of the WT1 isoforms in 36 primary leukemias and found that 17AA( þ )WT1 isoforms were dominantly expressed in all of these leukemias examined regardless of disease subtypes. Therefore, since suppression of the expression of 17AA( þ )WT1 isoforms should improve the sensi- Antiapoptotic function of WT1 in leukemia K Ito et al tivity of leukemia cells to chemotherapeutic drugs, 17AA( þ )WT1 isoforms should be a novel molecular target for treatment of leukemia.
Materials and methods
Cell lines and culture conditions
Three highly WT1-expressing leukemia cell lines, chronic myeloid leukemia cell line K562, acute myeloid leukemia cell line Kasumi-1, and acute promyelocytic leukemia cell line HL-60, and one WT1-non-expressing Burkit lymphoma cell line Daudi were cultured in RPMI1640 medium supplemented with 10% fetal bovine serum (FBS).
Antibodies
Monoclonal anti-bak (Oncogene Research Products, Boston, MA, USA), anti-WT1 (Dako, Carpinteria, CA, USA), antiactin (Chemicon, Temecula, CA, USA), anti-Bcl-XL (Chemicon, Temecula, CA, USA), anti-p21 (Oncogene Research Products, Boston, MA, USA), anti-caspase-9 (R&D Systems, Inc., Minneapolis, MN), anti-p27 (BD Biosciences, Pharmingen, San Jose, CA), polyclonal anti-bax (Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-bcl-2 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-cytochrome c (Pharmingen) antibodies, and goat anti-rabbit or anti-mouse IgG conjugated with alkaline phosphatase (Santa Cruz Biotechnology) were used as secondary antibodies in Western blot analysis. For immunocytochemistry, monocolonal antiHis tag (anti-Xpress) (Invitrogen, Carlsbad, CA, USA) and rabbit anti-mouse IgG conjugated with fluorescein isothiocyanate isomer1 (FITC) (DAKO, A/S, Denmark) were used.
Reagents zVAD-fmk (broad-caspase inhibitor), Ac-LEHD-CHO (inhibitor for caspase-9), Ac-DEVD-CHO (inhibitor for caspase-3), and Ac-IETD-CHO (inhibitor for caspase-8) (Peptide Institute Inc., Osaka, Japan) were used to inhibit caspase activity at the concentration of 100 mM. Etoposide (Wako, Osaka, Japan) and Doxorubicin (Sigma Chemical Co., Steinheim, Germany) were used to activate the intrinsic apoptosis pathway and induce apoptosis at the concentration of 100 mM and 100 nM, respectively. Soluble TRAIL (PEPROTECH EC, London, UK) was used to activate the extrinsic apoptosis pathway and induce apoptosis at the concentration of 500 ng/ml. The enzyme substrate Ac-DEVD-AFC (BIOBOL, Tebu, France), FAM-LEHD-FMK (Serologicals, Norcross, GA, USA), and IETDpNA (BioVision Lab, Palo Alto, CA, USA) were used to detect caspase-3-like, caspase-9-like, and caspase-8-like activities, respectively. The crosslinkers disuccinimidyl suberate (DSS) (Pierce Biotechnology, Rockford, IL, USA) was used in the detection of dimerization or oligomerization of Bax protein.
HisMock
His
Vector construction A pcDNA 3.1( þ ) (Invitrogen, Carlsbad, CA, USA) containing one each of four human WT1 isoforms
, and 17AA(À)/KTS(À)) was constructed and used for expression of one each of WT1 isoforms in K562 cells. The sequences of one each of four human WT1 isoforms and WT1 lacking zincfinger region that were cloned in a pUC119 vector were PCRamplified using Pfx Taq polymerase (Invitrogen, Carlsbad, CA, USA) and integrated into pcDNA 3.1/His vector (Invitrogen, Carlsbad, CA, USA). All the PCR-amplified sequences were confirmed for the absence of mutation by direct sequencing using BigDye Terminator V.1.1 cycle sequencing kit (Applied Biosystem, Branch berg, NJ, USA).
To prepare 17AA( þ )WT1-and 17AA(À)WT1-specific siRNA vector, oligonucleotides encoding dsRNA directing (5 0 -AGCTCCAGCTCAGTGAAATGGACAGAAGGG-3 0 ) in 17AA( þ )WT1 mRNA and the sequence corresponding to the ligated sequences flanking the 17AA region in 17AA(À)WT1 mRNA were chemically synthesized, respectively (Japan BioScience, Saitama, Japan), annealed, and inserted into tRNA-shRNA expression vector piGENE tRNA Pur (Clontech, CA, USA) or Gene Silence pGSU6 shRNA Vector (Gene Therapy Systems, Inc., San Diego, CA, USA) which co-expressed GFP. 
Transient expression of siRNA vectors
For transient transfection of siRNA vectors, K562, HL-60, Kasumi-1, and Daudi cells (2 Â 10 6 cells) were washed three times and incubated with 10 mg plasmid DNA in 300 ml medium (FBS-) in a 4-mm cuvette. Transfection was performed by electroporation (150 V, 1000 mF) using Gene Pulser Xcellt system (BioRad, CA, USA).
Stable expression of vectors
Mammalian expression vectors were linealized with PvuI and introduced into K562 cells by electroporation using Gene Pulsor II (BioRad, CA, USA). The cell clones that stably expressed the vectors were isolated using the corresponding selective antibiotics.
Analysis of apoptosis by flow cytometry
To assess apoptotic cells, 1 Â 10 5 cells were washed with PBS, and stained with Annexin V-FITC and PI at room temperature for 15 min in the dark using MEBCYTO Apoptosis Kit (Medical and Biological Laboratories Co., Ltd, Nagoya, Japan) according to the manufacturer's instructions. Then, the stained cells were analysed by FACScan flow cytometer (Becton Dickinson, San Jose, CA, USA). Apoptosis was shown as percentages of apoptotic cells to the total number of counted cells.
Determination of cytochrome c release
To assess the release of cytochrome c from mitochondria to cytoplasm, cells were washed once with PBS, lysed in ice-cold STE buffer (250 mM sucrose, 25 mM Tris, and 1 mM EDTA, pH 6.8), and immediately centrifuged at 15 000 g for 15 min. The supernatants were mixed with an equal volume of 2 Â Laemmeli's SDS sample buffer for Western blot analysis and stored at À201C until use.
Analysis of mitochondrial membrane potential loss
Changes in MMP following induction of apoptosis were assessed using MitoLight apoptosis detection kit (Chemicon International, Temecula, CA, USA) according to the manufacturer's instructions. In brief, after induction of apoptosis, cells were incubated at 371C for 15 min in reaction buffer containing MitoLight mitochondrial dye that stained mitochondria in living cells in a membrane potential-dependent fashion. Then, the status of mitochondrial membrane potential was analysed using a FACScan flow cytometer in the FL1 channel.
RNA isolation and RT-PCR
Total cellular RNA was isolated using ISOGEN (WAKO, Osaka, Japan). Total RNA (2 mg) was reverse transcribed using murine Maloney leukemia virus (M-MLV) reverse transcriptase according to the manufacturer's protocols (Promega, Madison, WI, USA). PCR was performed in a total volume of 20 ml with 1 ml cDNA synthesis mixture for 25 cycles of 941C denaturation (1 min), 601C annealing (1 min), and 721C extension (1.5 min). PCR primer was as follows. WT1: forward primer, 5 0 -GACCTGGAATCAGATGAA-3 0 , reverse primer, 5 0 -GAGAACTTTCGCTGACAAGTT-3 0 ; Actin: forward primer, 5 0 -CCCAGCACAATGAAGATCAA GATCAT-3 0 , reverse primer, 5 0 -ATCTGCTGGAAGGTGGA CAGCGA-3 0 .
Western blot analysis Cells were washed twice with PBS and lysed with 2 Â Laemmeli's SDS sample buffer. Proteins were separated by SDS-PAGE and transferred to Immobilon polyvinylidene difluoride membrane (Millipore Corp., Bedford, MA, USA). After blocking of non-specific binding, immunoblots were incubated with primary antibody followed by incubation with the appropriate anti-rabbit or anti-mouse IgG antibody conjugated with alkaline phosphatase, and visualized using BCIP/NBT kit (Nacalai Tesque, Kyoto, Japan).
Activities of caspases
Caspases 3-like, 9-like, and 8-like activities were measured as described previously (Shimizu et al., 1996) . Briefly, the cells were collected at various time points, lysed in lysis buffer (150 mM NaCl, 50 mM Tris-HCl (pH 7.4), 1 mM EDTA, 0.1% Triton-X) on ice for 30 min and centrifuged. The supernatant was stored at À201C until use. Concentration of proteins was determined using a Bio-Rad protein assay reagent by Bradford method. Then, the cytosol containing 50 mg of proteins was suspended in reaction buffer (50 mM Tris-HCl (pH 7.4), 1 mM EDTA, and 10 mM EGTA) containing 10 mM of the enzyme substrate Ac-DEVD-AFC (for caspase-3-like activity), FAM-LEHD-FMK (for caspase-9-like activity), or IETD-pNA (for caspase-8-like activity) and incubated at 371C for 1 h. The fluorescence at 485/535 nm (for caspases 3-and 9-like activities) or 405 nm (for caspase-8-like activity) was measured using a Spectra-Max Gemini XS fluorescence plate reader (Molecular Devices, Sunnyvale, CA, USA).
Detection of oligomerization of Bax
To detect oligomerization of Bax, 2 Â 10 6 K562 cells were collected, washed three times with PBS, incubated with PBS containing 1 mM of DSS at room temperature for 30 min, and then incubated with 100 mM Tris buffer (pH 7.4) for 15 min to quench the crosslinker.
Immunocytochemistry K562 cells attached onto glass slides by cytocentrifugation were fixed with 4% paraformaldehyde in PBS at room temperature for 20 min. Then, cells were permeabilized with methanol at room temperature for 5 min. After blocking (2% BSA, 0.1% NaN 3 , 0.2% Tween 20, 6.7% glycerol in PBS) for 45 min, the cells were stained with monoclonal anti-His tag (anti-Xpress) and rabbit anti-mouse IgG conjugated with fluorescein isothiocyanate isomer 1 (FITC) (DAKO, A/S, Denmark). Nucleic acid stain was preformed by using 100 ng/ml DAPI (4 0 ,6-amido-2-phenylindol) (Chemicon, Temecula, CA, USA). For staining of the mitochondria, K562 cells were incubated in the medium containing 100 nM Mitotracker Red 580 (Molecular Probe, Eugene, OR) at 371C for 30 min. After washes with cell culture medium, cells were observed by laser confocal microscopy, LSM 510 META (Carl Zeiss Inc., Oberkochen, Germany).
Statistical analysis
One-way analysis of variance followed by Fisher's PLSD was used to determine the statistical significance of apoptosis employing the STATVIEW software (Abacus Concepts, Inc., Berkeley, CA, USA).
